Table 1

Subject demographics and baseline characteristics (intent-to-treat population)

LBN
0.006% (n=82)
LBN
0.012% (n=85)
LBN
0.024% (n=83)
LBN
0.040% (n=81)
Latanoprost
0.005% (n=82)
Total (N=413)p Value
Age (years)
 Mean (SD)60.9 (11.39)61.6 (9.58)60.8 (11.47)60.3 (12.89)61.2 (11.92)61.0 (11.44)0.972†
 Median62.062.062.061.062.062.0
 Range24–8531–8438–8130–8529–8924–89
Gender, N (%)
 Male26 (31.7)39 (45.9)26 (31.3)38 (46.9)29 (35.4)158 (38.3)0.640‡
 Female56 (68.3)46 (54.1)57 (68.7)43 (53.1)53 (64.6)255 (61.7)
Race, N (%)
 White61 (74.4)61 (71.8)62 (74.7)56 (69.1)66 (80.5)306 (74.1)0.485‡
 Black or African American21 (25.6)23 (27.1)21 (25.3)23 (28.4)16 (19.5)104 (25.2)
 American Indian or Alaskan Native01 (1.2)0001 (1.2)
 Asian0001 (1.2)01 (1.2)
 Other0001 (1.2)01 (1.2)
Ethnicity, N (%)
 Hispanic or Latino5 (6.1)2 (2.4)8 (9.6)6 (7.4)11 (13.4)32 (7.7)
 Non-Hispanic and non-Latino77 (93.9)83 (97.6)75 (90.4)75 (92.6)71 (86.6)381 (92.3)
Treatment-naive subject, N (%)
 Yes35 (42.7)39 (45.9)36 (43.4)35 (43.2)35 (42.7)180 (43.6)0.874‡
 No47 (57.3)46 (54.1)47 (56.6)46 (56.8)47 (57.3)233 (56.4)
Previous IOP-lowering medication, N (%)*
 Prostaglandin analogue35 (74.5)38 (82.6)38 (80.9)35 (76.1)36 (76.6)182 (78.1)
 β-Blocker13 (27.7)17 (37.0)17 (36.2)15 (32.6)19 (40.4)81 (34.8)
 Carbonic anhydrase inhibitor10 (21.3)10 (21.8)6 (12.8)10 (21.7)7 (14.9)43 (18.5)
 Sympathomimetics5 (10.6)2 (4.3)3 (6.4)03 (6.4)13 (5.6)
Baseline (Visit 3, Day 1) IOP*
 Mean (SD)26.12 (1.82)26.25 (1.88)26.01 (1.67)26.04 (1.51)26.15 (1.79)0.909†
 Median25.6725.6725.6725.8325.67
 Range23.83–32.0022.67–31.8323.17–30.6724.00–30.8323.50–31.17
  • Specific drugs within the previous IOP-lowering medications categories were as follows: (1) prostaglandin analogues: latanoprost, bimatoprost and travaprost; (2) β-blockers: timolol and carteolol; (3) carbonic anhydrase inhibitors: brinzolamide and dorzolamide; and (4) sympathomimetics: brimonidine. In all, 46 eyes were being treated with combination products: dorzolamide–timolol, brimonidine–timolol, latanoprost–timolol, bimatoprost–timolol, travaprost–timolol and brinzolamide–timolol.

  • *Study eye.

  • †ANOVA model with treatment effect.

  • ‡χ2 Test comparing number of subjects among all treatment groups.

  • IOP, intraocular pressure; LBN, latanoprostene bunod.